Matters of legal in nature including licensing, intellectual property, and lawsuits.
Tue 11th May 2021 Today the Court of Appeals for the Federal Circuit issued a unanimous Precedential Opinion and Judgment affirming the jury’s March 2020 verdict in the PacBio v. Oxford Nanopore case, that invalidated a number of PacBio patents. This has been a long running dispute in which Oxford Nanopore has repeatedly prevailed. In... Read more
Xylem Becomes Platinum Esri Partner, Will Create Joint Solutions, Collaborate On Marketing Water Operators To Benefit From Better Network Visibility, Optimized Infrastructure, Lower Costs RYE BROOK, N.Y.–(BUSINESS WIRE)–Apr. 28, 2021– Xylem (NYSE:XYL), a leading water technology company dedicated to solving the world’s greatest water challenges, has forged a partnership with Esri, the global leader in... Read more
Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society WALTHAM, Mass. (April 28, 2021) — Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval... Read more
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s comprehensive genomic profiling assay, TruSight™ Oncology 500 (TSO 500). This companion diagnostic for multiple hematologic indications will be the first to use TSO 500 with... Read more
85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE study OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study OCREVUS-treated patients show highest adherence and persistence rates... Read more
MINNEAPOLIS, April 14, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, for its therapeutic development pipeline. Bio-Techne is a global life sciences company providing... Read more
CHELMSFORD, Mass., April 5, 2021 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 which includes a 40-minute webcast beginning at 12:45 p.m. ET. The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/events. A... Read more
CRISPRi Innovations Provide Expanded Experimental Options and Flexibility For Researchers Facilitating Disease & Drug Research WALTHAM, Mass.–(BUSINESS WIRE)–Mar. 29, 2021– Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists... Read more
CHELMSFORD, Mass., March 15, 2021 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 23, 2021 which includes a 35-minute webcast beginning at 1:15 p.m. ET. The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/events. ... Read more